Advertisement

Vernalis announces positive results for Parkinson's Disease treatment study

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

The study examined the relationship between dose, plasma concentration and blockade of the so-called "A2A" receptor using positron emission tomography scanning and included a preliminary evaluation, using functional magnetic resonance imaging of the effects of V81444, the particular antangonist, on cognitive function.

Advertisement - Article continues below

The study demonstrated that full A2A blockade could be achieved with single doses that were within the range of doses previously shown to be well tolerated with no safety concerns.

As such, the study has provided confirmation of the appropriate dose to be used in the forthcoming clinical proof-of-concept trial.

Vernalis now plans to initiate, in the first half of next year, a Phase IIa proof-of-concept study to further evaluate the pharmacokinetics, safety and tolerability of V81444 in patients, together with an evaluation of efficacy in a target patient population.

Ian Garland, Chief Executive Officer of Vernalis, commented: "We are very pleased with these results and are already actively preparing for the continued development of this exciting programme over the next 12 months".

Vernalis's share price was up 0.55% to 23p at 09:27 on Wednesday morning.

MF

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?
UK Economy

Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?

John Stepek runs his eye over the chancellor's £30bn stimulus package and asks if it's enough to get the economy back on its feet after months of lock…
9 Jul 2020
Have small companies lost their edge?
Sponsored

Have small companies lost their edge?

SPONSORED CONTENT – The tectonic plates beneath the modern investing landscape appear to have started moving in new directions
26 Jun 2020